Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
AssigneeZonagen, Inc.
InventorsJoseph S. Podolski, Ronald Wiehle
Life of this patent
Estimating the term…
Abstract
The present invention discloses compositions and methods useful for treating wasting, especially a loss of muscle mass. The present invention also discloses compositions and methods useful for treating lipodystrophy. The compositions and methods of the present invention are particularly beneficial to HIV-infected individuals.
Claims14
A composition comprising 0% to about 29% w/w of cis-clomiphene and about 100% to about 71% trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
A composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients and wherein the ratio of trans-clomiphene and cis-clomiphene is greater than 71/29.
A composition consisting essentially of trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
A method for treating wasting in a mammal, comprising administering to the mammal an effective amount of a composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of trans-clomiphene to cis-clomiphene is greater than 71/29.
A method for modulating muscle mass muscle mass in a mammal, comprising administering to the mammal an effective amount of a composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of trans-clomiphene to cis-clomiphene in said composition is greater than 71/29.
A method for modulating cholesterol levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of trans-clomiphene to cis-clomiphene is greater than 71/29.
A method for treating lipodystrophy in a mammal, comprising administering to the mammal an effective amount of a composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of trans-clomiphene to cis-clomiphene is greater than 71/29.
A method for modulating lymphocyte levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising cis-clomiphene and trans-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of trans-clomiphene to cis-clomiphene is greater than 71/29.
Dependencies are inferred from the claim text.